New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
16:09 EDTAMRIAMRI closes Cedarburg deal, sees adding 6c-7c to FY14 adjusted EPS
AMRI announced that it has completed the previously announced acquisition of Cedarburg Pharmaceuticals. Total consideration paid was $41M, including assumption of certain liabilities. AMRI financed the transaction with cash on hand. The acquisition is expected to add between $13M-$14M to AMRI's revenue in FY14. AMRI anticipates full year run-rate synergies of approximately $1.5M of EBITDA within 12 months of closing and the acquisition is expected to be accretive to AMRI's FY14 adjusted diluted EPS in the range of 6c-7c per share.
News For AMRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
11:16 EDTAMRIAMRI says Albuquerque, NM sterile injectable facility resumes full operations
AMRI announced that its Albuquerque, N.M. sterile injectable facility has resumed full manufacturing operations. As previously announced, in September AMRI identified an environmental deviation in one manufacturing suite as a result of a weather related business interruption. The resulting remediation has now been completed.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use